Hits:
Indexed by:期刊论文
Date of Publication:2011-12-01
Journal:METABOLOMICS
Included Journals:Scopus、SCIE
Volume:7
Issue:4
Page Number:549-558
ISSN No.:1573-3882
Key Words:Support vector machine; Genetic algorithm; Random forest; Liver diseases; Metabonomics; Metabolomics
Abstract:Metabolic markers are the core of metabonomic surveys. Hence selection of differential metabolites is of great importance for either biological or clinical purpose. Here, a feature selection method was developed for complex metabonomic data set. As an effective tool for metabonomics data analysis, support vector machine (SVM) was employed as the basic classifier. To find out meaningful features effectively, support vector machine recursive feature elimination (SVM-RFE) was firstly applied. Then, genetic algorithm (GA) and random forest (RF) which consider the interaction among the metabolites and independent performance of each metabolite in all samples, respectively, were used to obtain more informative metabolic difference and avoid the risk of false positive. A data set from plasma metabonomics study of rat liver diseases developed from hepatitis, cirrhosis to hepatocellular carcinoma was applied for the validation of the method. Besides the good classification results for 3 kinds of liver diseases, 31 important metabolites including lysophosphatidylethanolamine (LPE) C16:0, palmitoylcarnitine, lysophosphatidylethanolamine (LPC) C18:0 were also selected for further studies. A better complementary effect of the three feature selection methods could be seen from the current results. The combinational method also represented more differential metabolites and provided more metabolic information for a "global" understanding of diseases than any single method. Further more, this method is also suitable for other complex biological data sets.
Pre One:Application of L-EDA in metabonomics data handling: global metabolite profiling and potential biomarker discovery of epithelial ovarian cancer prognosis
Next One:Classification and differential metabolite discovery of liver diseases based on plasma metabolic profiling and support vector machines